Clinical outcomes of patients with EGFR-mutated NSCLC developing interstitial lung disease during first-line osimertinib therapy: a sub-analysis of the Reiwa study
Patients with interstitial lung disease grade 3-4 had poorer survival during the first-line osimertinib therapy. A substantial risk of interstitial lung disease recurrence was associated with post-osimertinib therapy. Trial registration code: UMIN000038683.
Authors
- Kiyotaka Yoh
- Kohei Uemura
- Kazuma Kishi (ORCID: https://orcid.org/0000-0002-6801-0147)
- Takayuki Kobayashi (ORCID: https://orcid.org/0000-0001-5523-2982)
- Go Naka (ORCID: https://orcid.org/0000-0002-3804-0898)
- Kageaki Watanabe (ORCID: https://orcid.org/0000-0002-8420-5606)
- Yukio Hosomi (ORCID: https://orcid.org/0000-0002-3849-5905)
- Kazuhiro Usui (ORCID: https://orcid.org/0000-0002-4492-9327)
- Hideo Kunitoh
- Shu Tamano
Institutions
- Toho University (JP)
- Tokyo University of Information Sciences (JP)
- NTT Medical Center (JP)
- Tokyo Metropolitan Komagome Hospital (JP)
- National Center for Global Health and Medicine (JP)
- Toho University Omori Medical Center (JP)
- Japanese Red Cross Medical Center (JP)
- National Cancer Center Hospital East (JP)
- The University of Tokyo (JP)
Publication Details
- Journal
- Japanese Journal of Clinical Oncology
- Published
- 2024-12-20
- DOI
- https://doi.org/10.1093/jjco/hyae178
- Citations
- 1
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.42
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Chugai Pharmaceutical
- Daiichi Sankyo Europe